Briviact® Europe In Europe, Briviact® (brivaracetam) is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. USA In the US, BRIVIACT® (brivaracetam) CV is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Prescribing information Europe SmPC Briviact® (EU). Sourced from www.ema.europa.eu. Prescribing information USA BRIVIACT® US Prescribing information - May 2023
